Sk Chemicals Co., Ltd.

Ewha University-Industry Collaboration Foundation

Seoul National University

Expression Pathology Incorporated

In2gen Co., Ltd.

Yung-Jue Bang

Hun-Taek Kim

Dae-Kee Kim

Myoung-Soon Park

Il-Sang Cho

Joon Hun Choi

Young Jae An

Todd Hembrough

Jae Won Choi

Eunkyung An

In-Young Song

Yong-Kook Kim

Ho Soon Lee

Do-Youn Oh

Jin-Wook Jang

Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.

Quantifying Her2 protein for optimal cancer therapy

A compound of the formula: Wherein A, A, X, Rand R3 are as defined herein, or a composition containing the same, which compound is useful in treating renal-, liver- or pulmonary fibrosis.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-&#x3b2; and/or activin signaling pathway in mammals.

The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.

Factor VIII polypeptide

Growing community of inventors

Seoul, South Korea

Yung-Jue Bang